Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitro

被引：19
|
作者：
Xiong, Hua-Long [1 ,2 ]
Cao, Jia-Li [1 ,2 ,3 ]
Shen, Chen-Guang [4 ,5 ]
Ma, Jian [1 ,2 ]
Qiao, Xiao-Yang [1 ,2 ]
Shi, Tian-Shu [1 ,2 ]
Ge, Sheng-Xiang [1 ,2 ]
Ye, Hui-Ming [2 ,3 ]
Zhang, Jun [1 ,2 ]
Yuan, Quan [1 ,2 ]
Zhang, Tian-Ying [1 ,2 ]
Xia, Ning-Shao [1 ,2 ]
机构：
[1] Xiamen Univ, Natl Inst Diagnost & Vaccine Dev Infect Dis, Sch Life Sci, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen, Peoples R China
[2] Xiamen Univ, Sch Publ Hlth, Xiamen, Peoples R China
[3] Xiamen Univ, Sch Med, Women & Childrens Hosp, Dept Clin Lab, Xiamen, Peoples R China
[4] Southern Univ Sci & Technol, State Key Discipline Infect Dis, Hosp Affiliated 2,Shenzhen Peoples Hosp 3, Shenzhen Key Lab Pathogen & Immun,Natl Clin Res C, Shenzhen, Peoples R China
[5] Southern Med Univ, Sch Publ Hlth, Guangzhou, Peoples R China
来源：
FRONTIERS IN PHARMACOLOGY | 2021年 / 11卷
基金：
中国国家自然科学基金;
关键词：
drug screening; SARS-CoV-2; pseudovirus assay; vesicular stomatitis virus; drug combination; ENTRY;
D O I：
10.3389/fphar.2020.609592
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
To identify drugs that are potentially used for the treatment of COVID-19, the potency of 1403 FDA-approved drugs were evaluated using a robust pseudovirus assay and the candidates were further confirmed by authentic SARS-CoV-2 assay. Four compounds, Clomiphene (citrate), Vortioxetine, Vortioxetine (hydrobromide) and Asenapine (hydrochloride), showed potent inhibitory effects in both pseudovirus and authentic virus assay. The combination of Clomiphene (citrate), Vortioxetine and Asenapine (hydrochloride) is much more potent than used alone, with IC50 of 0.34 mu M.
引用
下载
收藏
页数：8
相关论文
共 50 条
  • [41] Identification of SARS-CoV-2 main protease inhibitors from FDA-approved drugs by artificial intelligence-supported activity prediction system
    Komatsu, Hirotsugu
    Tanaka, Takeshi
    Ye, Zhengmao
    Ikeda, Ken
    Matsuzaki, Takao
    Yasugi, Mayo
    Hosoda, Masato
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (05): : 1767 - 1775
  • [42] Identification of FDA-approved drugs against SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) through computational virtual screening
    Jade, Dhananjay
    Alzahrani, Areej
    Critchley, William
    Ponnambalam, Sreenivasan
    Harrison, Michael A.
    STRUCTURAL CHEMISTRY, 2023, 34 (03) : 1005 - 1019
  • [43] Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2
    Dittmar, Mark
    Lee, Jae Seung
    Whig, Kanupriya
    Segrist, Elisha
    Li, Minghua
    Kamalia, Brinda
    Castellana, Lauren
    Ayyanathan, Kasirajan
    Cardenas-Diaz, Fabian L.
    Morrisey, Edward E.
    Truitt, Rachel
    Yang, Wenli
    Jurado, Kellie
    Samby, Kirandeep
    Ramage, Holly
    Schultz, David C.
    Cherry, Sara
    CELL REPORTS, 2021, 35 (01):
  • [44] Potential Inhibitors of SARS-CoV-2 Main Protease (Mpro) Identified from the Library of FDA-Approved Drugs Using Molecular Docking Studies
    Verma, Dipesh Kumar
    Kapoor, Srajan
    Das, Satyajeet
    Thakur, Krishan Gopal
    BIOMEDICINES, 2023, 11 (01)
  • [45] Virtual Screening for FDA-Approved Drugs That Selectively Inhibit Arginase Type 1 and 2
    Detroja, Trishna Saha
    Samson, Abraham O.
    MOLECULES, 2022, 27 (16):
  • [46] Repurposing of FDA Approved Drugs Against SARS-CoV-2 Papain-Like Protease: Computational, Biochemical, and in vitro Studies
    Kulandaisamy, Rajkumar
    Kushwaha, Tushar
    Dalal, Anu
    Kumar, Vikas
    Singh, Deepa
    Baswal, Kamal
    Sharma, Pratibha
    Praneeth, Kokkula
    Jorwal, Pankaj
    Kayampeta, Sarala R.
    Sharma, Tamanna
    Maddur, Srinivas
    Kumar, Manoj
    Kumar, Saroj
    Polamarasetty, Aparoy
    Singh, Aekagra
    Sehgal, Deepak
    Gholap, Shivajirao L.
    Appaiahgari, Mohan B.
    Katika, Madhumohan R.
    Inampudi, Krishna K.
    FRONTIERS IN MICROBIOLOGY, 2022, 13
  • [47] Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation
    Serra, Angela
    Fratello, Michele
    Federico, Antonio
    Ojha, Ravi
    Provenzani, Riccardo
    Tasnadi, Ervin
    Cattelani, Luca
    del Giudice, Giusy
    Kinaret, Pia A. S.
    Saarimaki, Laura A.
    Pavel, Alisa
    Kuivanen, Suvi
    Cerullo, Vincenzo
    Vapalahti, Olli
    Horvath, Peter
    Di Lieto, Antonio
    Yli-Kauhaluoma, Jari
    Balistreri, Giuseppe
    Greco, Dario
    BRIEFINGS IN BIOINFORMATICS, 2022, 23 (01)
  • [48] Possible FDA-approved drugs to treat Ebola virus infection
    Shu Yuan
    Infectious Diseases of Poverty, 4
  • [49] A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection
    Barrows, Nicholas J.
    Campos, Rafael K.
    Powell, Steven T.
    Prasanth, K. Reddisiva
    Schott-Lerner, Geraldine
    Soto-Acosta, Ruben
    Galarza-Munoz, Gaddiel
    McGrath, Erica L.
    Urrabaz-Garza, Rheanna
    Gao, Junling
    Wu, Ping
    Menon, Ramkumar
    Saade, George
    Fernandez-Salas, Ildefonso
    Rossi, Shannan L.
    Vasilakis, Nikos
    Routh, Andrew
    Bradrick, Shelton S.
    Garcia-Blanco, Mariano A.
    CELL HOST & MICROBE, 2016, 20 (02) : 259 - 270
  • [50] Possible FDA-approved drugs to treat Ebola virus infection
    Yuan, Shu
    INFECTIOUS DISEASES OF POVERTY, 2015, 4
12345